-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2025-522878-36-00
5
2026-04-20
Chronic Spontaneous Urticaria
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-511458-32-00
5
2025-06-15
Ulcerative colitis
-
2024-516360-29-00
4
2025-04-25
Complicated Urinary Tract Infection (cUTI),
Acute Pyelonephritis (AP)
-
2023-508015-23-00
5
2025-04-11
Ovarian cancer recurrent
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2024-512707-40-00
4
2024-11-07
RELAPSING MULTIPLE SCLEROSIS
-
2023-504231-41-01
4
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-501703-27-00
5
2023-07-05
Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2025-523544-12-00
5
2026-06-02
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-521875-30-00
4
2026-05-28
Acute myeloid leukaemia
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma